輝瑞收購Redvax加速疫苗業務布局

　　當地時間2015年1月5日，輝瑞宣布其已獲得Redvax GmbH的控股權，Redvax GmbH是一家瑞士的私人控股生物制藥公司，總部位于蘇黎世。這項交易包括一項巨細胞病毒疫苗（CMV）和一項未公開的疫苗相關的知識產權和技術平臺。

　　通過收購Redvax獲得的CMV疫苗項目將進一步完善輝瑞的疫苗業務，并且將使其在CMV疫苗的研發中占據領導地位。

　　CMV是一種皰疹病毒，約50%~90%的成人會感染該病毒，絕大部分人在感染該病毒時沒有明顯癥狀。如果孕齡女性沒有CMV抗體，她們在孕期時會非常容易感染CMV病毒，進而影響胎兒發育導致畸形。

　　美國疾病預防控制中心預測，在美國每年大約有5000名兒童因受CMV影響而致病（包括心臟疾病、畸形和智力殘疾），為此每年的醫療費用支出達18.6億美元，每個孩子花費超過30萬美元。為降低CMV病毒帶來的影響， 美國醫學研究所將CMV疫苗研發列為最高優先級項目。

　　Pfizer Acquires Redvax GmbH

　　Acquisition Provides Pfizer with a Preclinical CMV Vaccine Candidate

　　 Monday, January 5, 2015  -7:30amEST

　　Pfizer Inc. today announced that it has acquired a controlling interest in Redvax GmbH, a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. This transaction provides access to a preclinical human cytomegalovirus (CMV) vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program.

　　The CMV vaccine program will complement Pfizer's robust research portfolio of high-quality and life-saving investigational vaccines and place Pfizer among the leaders in CMV research and development. CMV is a herpes virus, infecting 50-90% of the adult population, with a majority remaining asymptomatic. A large segment of young adults, especially women of childbearing age who remain CMV negative, are at high risk of CMV infection during pregnancy and of passing the infection on to the unborn child (congenital infection). There are potentially serious and lifelong consequences for babies born with the disease. One out of every five children born with CMV infection may experience hearing loss and severe neurologic disorders. More children have disabilities due to congenital CMV than other well-known infections and syndromes, including Down syndrome, fetal alcohol syndrome, spina bifida, and pediatric HIV/AIDS.4

　　"We are working to bring innovative vaccines to market that prevent and treat serious diseases," said Kathrin U. Jansen, Ph.D., senior vice president & CSO Vaccine Research & Early Development for Pfizer. "Through the acquisition of the Redvax innovative CMV vaccine platform and expertise we will seek to develop a vaccine to prevent a difficult disease that can have a devastating and lifelong impact on young children."

　　The U.S. Centers for Disease Control and Prevention (CDC) estimate that, in the U.S., approximately 5,000 children each year develop lasting health problems caused by CMV such as hearing or vision loss, and mental disability. The Institute of Medicine (IOM) has ranked the development of a CMV vaccine as a highest priority because of the lives it would save and the disabilities it would prevent. The estimated costs associated with CMV disease for the U.S. health care system amounts to at least $1.86 billion annually. CMV expenses can run more than $300,000 per child.

　　Christian Schaub, CEO of Redbiotec and Managing Director of Redvax commented, "We are pleased to have completed this deal with Pfizer, a global leader in vaccines. This represents an important step toward the development of a much needed vaccine for CMV, a disease that has a devastating impact on children and families. We believe that combining Redvax's assets with Pfizer's commitment, expertise and resources will significantly enhance the potential of developing this important vaccine."

　　About Pfizer Inc.

　　At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com.

　　About Redvax GmbH

　　Redvax is a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. Redvax is a preclinical stage company. The company develops multi-component virus-like particles (VLPs) and other protein assemblies for vaccine development in the field of CMV and a further undisclosed field.